Literature DB >> 7895015

Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder.

I E Scheffer1, K P Bhatia, I Lopes-Cendes, D R Fish, C D Marsden, E Andermann, F Andermann, R Desbiens, D Keene, F Cendes.   

Abstract

The disorder of autosomal dominant nocturnal frontal lobe epilepsy has recently been identified, and is now delineated in detail. A phenotypically homogeneous group of five families from Australia, Britain and Canada, containing 47 affected individuals, was studied. The largest family contained 25 affected individuals spanning six generations. This disorder is characterized by clusters of brief nocturnal motor seizures, with hyperkinetic or tonic manifestations. Subjects often experienced an aura, and remained aware throughout the attacks. Seizures occurred in clusters (mean eight attacks/night) typically as the individual dozed, or shortly before awakening. The epilepsy usually began in childhood, and persisted through adult life, with considerable intra-family variation in severity. Seizures were often misdiagnosed as benign nocturnal parasomnias, psychiatric and medical disorders. Interictal EEG studies were unhelpful. Ictal video-EEG studies showed that the attacks were partial seizures with frontal lobe seizure semiology. Neuro-imaging was normal. Carbamazepine monotherapy was frequently effective. This disorder showed autosomal dominant inheritance. Recognition of this entity is clinically important for diagnosis, appropriate therapy and genetic counselling. Moreover, this disorder now offers an opportunity to identify a gene for partial epilepsy.

Entities:  

Mesh:

Year:  1995        PMID: 7895015     DOI: 10.1093/brain/118.1.61

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  69 in total

Review 1.  Ion channels and neurology.

Authors:  S M Zuberi; M G Hanna
Journal:  Arch Dis Child       Date:  2001-03       Impact factor: 3.791

2.  Genetics of Epilepsy in Clinical Practice.

Authors:  Samuel F Berkovic
Journal:  Epilepsy Curr       Date:  2015 Jul-Aug       Impact factor: 7.500

3.  Diagnosis and treatment of paroxysmal dyskinesias revisited.

Authors:  Iris Unterberger; Eugen Trinka
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 4.  Nocturnal frontal lobe epilepsy.

Authors:  Lino Nobili; Paola Proserpio; Romina Combi; Federica Provini; Giuseppe Plazzi; Francesca Bisulli; Laura Tassi; Paolo Tinuper
Journal:  Curr Neurol Neurosci Rep       Date:  2014-02       Impact factor: 5.081

5.  Two mutations linked to nocturnal frontal lobe epilepsy cause use-dependent potentiation of the nicotinic ACh response.

Authors:  A Figl; N Viseshakul; N Shafaee; J Forsayeth; B N Cohen
Journal:  J Physiol       Date:  1998-12-15       Impact factor: 5.182

Review 6.  The sleep manifestations of frontal lobe epilepsy.

Authors:  Christopher P Derry
Journal:  Curr Neurol Neurosci Rep       Date:  2011-04       Impact factor: 5.081

Review 7.  Nicotinic acetylcholine receptors in health and disease.

Authors:  J Lindstrom
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

8.  Nicotine normalizes intracellular subunit stoichiometry of nicotinic receptors carrying mutations linked to autosomal dominant nocturnal frontal lobe epilepsy.

Authors:  Cagdas D Son; Fraser J Moss; Bruce N Cohen; Henry A Lester
Journal:  Mol Pharmacol       Date:  2009-02-23       Impact factor: 4.436

9.  Familial aggregation of focal seizure semiology in the Epilepsy Phenome/Genome Project.

Authors:  Steven Tobochnik; Robyn Fahlstrom; Catherine Shain; Melodie R Winawer
Journal:  Neurology       Date:  2017-05-31       Impact factor: 9.910

10.  Human slack potassium channel mutations increase positive cooperativity between individual channels.

Authors:  Grace E Kim; Jack Kronengold; Giulia Barcia; Imran H Quraishi; Hilary C Martin; Edward Blair; Jenny C Taylor; Olivier Dulac; Laurence Colleaux; Rima Nabbout; Leonard K Kaczmarek
Journal:  Cell Rep       Date:  2014-12-04       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.